Amid the Covid-19 crisis, India and the US are discussing a limited trade deal. The two sides are reportedly considering bringing the GSP benefits under this package.
As scientists try out new drug combinations and look for clues in existing cancer therapies, ThePrint brings you the latest on studies on Covid-19 patients.
The health workers will be observed for up to 4 months in 5 cities. The study will estimate incidence rate of the infection & side-effects in health workers.
US FDA has highlighted side-effects of HCQ, especially on the heart, and said its use should be restricted to clinical trials or some hospitalised Covid-19 cases.
The government also plans to export HCQ, used for coronavirus treatment, to 62 countries after ensuring strategic storage of the medicine for domestic use.
India is learnt to have added Malaysia to the list of countries where it exports hydroxychloroquine, an anti-malarial drug touted as a promising cure for Covid-19.
The trial assumes the ICMR-recommended HCQ regimen is an ‘effective treatment’. However, ICMR chief epidemiologist says there isn’t enough evidence behind this.
Pulmonologist Dr Ravi Dosi, who leads 100-member team at the Indore hospital, tells ThePrint TCZ fights off 'cytokines' blamed for causing mortality in critically ill Covid patients.
Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.
PTC Industries is investing Rs 1,000 cr in 4 manufacturing plants in UP, has already started supplying titanium parts to BAE Systems for its M-777 howitzers that India also uses.
Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.
COMMENTS